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Duchenne muscular dystrophy is primarily characterized by progressive muscle
wasting due to deficiency in the membrane cytoskeletal protein dystrophin but
is also associated with body-wide cellular disturbances in a variety of non-muscle
tissues. In this study, we have focused on the comparative proteomic analysis of
the spleen and established considerable changes in this crucial secondary
lymphoid organ from the genetic mdx-4cv mouse model of dystrophinopathy.
An apparent short isoform of dystrophin and associated glycoproteins were iden-
tified in spleen bymass spectrometry but appear not be affected in muscular dys-
trophy. In contrast, the mdx-4cv spleen showed significant proteome-wide
changes in other protein species that are involved in metabolism, signaling, and
cellular architecture. Since the spleen plays a key role in the immune response,
these proteomic alterations may reflect pathophysiological cross talk between
the lymphoid system and dystrophic muscles, which are affected by both fiber
degeneration and inflammation.
INTRODUCTION
The neuromuscular disorder Duchenne muscular dystrophy is due to primary abnormalities in the DMD
gene (Guiraud et al., 2015), which encodes several different isoforms of the protein dystrophin (Muntoni
et al., 2003). Large-scale and antibody-based surveys of the tissue-specific presence of individual proteins
provide excellent information on the distribution of protein markers throughout the body (Thul and Lind-
skog, 2018). However, often the reliance on a single, albeit highly specific, antibody for antigen detection
does not take into account the existence of multiple protein isoforms with greatly differing cellular expres-
sion patterns. This is especially apparent in the case of the extremely large 79 exon-spanning DMD gene,
which contains seven promoters that drive the tissue-specific expression of various dystrophin isoforms of
differingmolecular mass (Muntoni et al., 2003). This includes three full-length isoforms of apparent 427 kDa,
i.e., Dp427-M in contractile tissues, Dp427-B in the brain, and Dp427-P in Purkinje cells. Shorter dystrophin
isoforms of approximately 116–260 kDa are represented by Dp116-S in Schwann cells, Dp140-B/K in brain
and kidney, and Dp260-R in the retina. In addition, an ubiquitous proteoform named Dp71-G exists in the
brain and various other tissues (Naidoo and Anthony, 2020).
Dystrophinopathies belong to a group of inherited degenerative diseases of muscles (Mercuri et al., 2019;
Thompson et al., 2020) that are characterized by progressive changes in the skeletal musculature, including
degeneration of contractile fibers, sterile inflammation, fatty tissue infiltration, and reactive myofibrosis (Al-
len et al., 2016; Dowling et al., 2020a; Shin et al., 2013; Smith and Barton, 2018; Tidball et al., 2018). The
recent mass spectrometry-based proteomic profiling of the vastus lateralis muscle from patients with
Duchenne muscular dystrophy has confirmed severe extracellular and cytoskeletal dysregulation in
dystrophinopathy (Capitanio et al., 2020). Additional complications manifest themselves as metabolic ab-
normalities, hormonal disturbances, scoliosis, neuronal deficiencies, and late-onset cardio-respiratory im-
pairments (Birnkrant et al., 2018; Meyers and Townsend, 2019; Saure et al., 2018). Thus, although X-linked
muscular dystrophy is primarily a monogenetic disease of contractile tissues, the complexity of its second-
ary pathophysiology makes it a neuromuscular disorder with a high degree of vulnerability of other tissue
and organ systems.
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ArticleAnimal models of Duchenne muscular dystrophy have been instrumental for studying the molecular and
cellular details of progressive degeneration in dystrophin-deficient muscle tissues, as well as testing of
novel experimental treatment strategies to counteract the dystrophic phenotype (McGreevy et al., 2015;
Rodrigues et al., 2016; Wilson et al., 2017). One of the most frequently used models of dystrophinopathy
is themdx-23mouse, which represents a naturally occurring mutant with a premature stop codon-inducing
mutation in exon 23 of the DMD gene (Sicinski et al., 1989). Hence, in analogy to progressive forms of hu-
man dystrophinopathy, this animal model almost completely lacks the full-length dystrophin isoform
Dp427-M (Partridge, 2013). An alternative mdx-type mouse model (mdx-4cv) was generated by chemical
mutagenesis with N-ethyl-N-nitrosourea (Chapman et al., 1989) and resulted in a C to T transition at
base 7,916 in exon 53, generating an ochre codon (Banks et al., 2010; Shin et al., 2011; Tichy and Mourkioti,
2017). Importantly, themdx-4cvmodel is typified by an approximately 10-fold lower rate of dystrophin-pos-
itive revertant fibers as compared with the conventional mdx-23 mouse (Danko et al., 1992; Im et al., 1996;
Judge et al., 2006). This feature of the genetic mouse model reflects more accurately the cellular charac-
teristics of affected skeletal muscles from patients with Duchenne muscular dystrophy. Consequently the
mdx-4cvmusculature represents an attractive tissue source for the systematic evaluation of new therapeu-
tic approaches, such as exon skipping following intramuscular injections of antisense oligomers (Mitrpant
et al., 2009), viral vector injection into neonatal muscles for the stable restoration of dystrophin expression
(Kimura et al., 2010), or CRISPR-Cas9-based dystrophin gene editing (Bengtsson et al., 2017).
Previous mass spectrometric investigations focusing on the mdx-4cv mouse have established differential
changes in the tissue proteome from various skeletal muscles, the heart, the brain, the liver, and the kidney
(Murphy et al., 2015, 2016; 2018a, 2019a; 2019b; Dowling et al., 2020b) and have identified elevated levels of
biofluid-associated markers in saliva, serum, and urine (Murphy et al., 2017, 2018b; Gargan et al., 2020). In
this study, we have extended the proteomic characterization of body-wide alterations in the mdx-4cv
mouse model of dystrophinopathy to the spleen, a secondary lymphoid organ that consists of two main
types of tissue, the blood-filled red pulp and the lymphatic white pulp (Mebius and Kraal, 2005). The
main functions of the spleen include the removal of abnormal erythrocytes, antigen detection, and anti-
body production (Lewis et al., 2019). In dystrophic organisms with an almost complete loss of the full-length
Dp427-M isoform of dystrophin, abnormalities in the spleen were previously reported to include morpho-
logical adaptations in relation to lymph nodes in the white pulp region of the mdx mouse spleen (Santos
et al., 2013), as well as altered levels of splenic inflammatory monocytes and increasedmigration of immune
cells from the splenic reservoir to injured dystrophic fibers (Farini et al., 2016; Giordano et al., 2015; Mojum-
dar et al., 2014, 2016; Ouisse et al., 2019; Rizzo et al., 2020).
The proteomic survey presented here has initially identified the experimentally assessable protein constituents
of themouse spleen with the help of anOrbitrap Fusion Tribridmass spectrometer. The established splenic pro-
tein catalog was screened for the presence of markers of spleen function and the potential presence of dystro-
phin, which had previously been suggested by the RT-PCR analysis of dystrophin in non-muscle tissues (Tokarz
et al., 1998), as well as the more widely distributed class of dystrophin-associated proteins. Comparative mass
spectrometric analyses of wild-type versusmdx-4cv tissue extracts were then used to determine potential pro-
teome-wide changes due to deficiency in dystrophin isoform Dp427-M. The proteomic findings suggest that a
variety of metabolic and cellular processes are affected in themdx-4cv spleen, which confirms the usefulness of
this genetic mouse model for studying the complex pathology of Duchenne muscular dystrophy. A pathophys-
iological connection appears to exist between skeletal muscle wasting, which is characterized by progressive fi-
ber degeneration and inflammation (Allen et al., 2016; Tidball et al., 2018), and alterations in the lymphoid system
due to primary abnormalities in the dystrophin gene (Rizzo et al., 2020).
RESULTS
In order to evaluate the complex pathogenesis of X-linked muscular dystrophy, this study has focused on
the proteomic characterization of potential secondary effects in a non-muscle organ, the spleen, in the es-
tablished mdx-4cv mouse model of dystrophinopathy. Prior to the comparative mass spectrometric anal-
ysis of this secondary lymphoid organ, the spleen proteome was evaluated for the presence of dystrophin
and spleen marker proteins.
Mass Spectrometric Identification of the Splenic Isoform of Dystrophin
To overcome the restricted specificity of protein isoform coverage by antibody screening using standard
immunochemical methodology (Thul and Lindskog, 2018), we have employed here a more sensitive2 iScience 23, 101500, September 25, 2020






P11531 Dystrophin Dp71 Dmd 2 6 6 71
Q62165 Dystroglycan Dag1 13 10 10 96.8
P82349 Beta-sarcoglycan Sgcb 5 1 1 34.9
P82347 Delta-sarcoglycan Sgcd 13 3 3 32.1
O70258 Epsilon-
sarcoglycan
Sgce 2 1 1 49.7
Q9D2N4 Alpha-
dystrobrevin
Dtna 6 2 2 84
Q61234 Alpha-1-
syntrophin
Snta1 6 2 1 53.6
Q99L88 Beta-1-syntrophin Sntb1 6 3 1 58




Articleproteomic screening approach with an Orbitrap Fusion Tribrid mass spectrometer for determining the po-
tential presence of low levels of dystrophin in the spleen. As listed in Table 1, dystrophin and various dys-
trophin-associated proteins were clearly identified by this method, including an apparent short isoform of
dystrophin, dystroglycan, beta-sarcoglycan, delta-sarcoglycan, epsilon-sarcoglycan, alpha-dystrobrevin,
alpha-1-syntrophin, and beta-1-syntrophin. Dystrophin was recognized by six unique peptides, and these
sections of the dystrophin sequence clearly aligned with the domain of the dystrophin protein that is close
to the carboxy terminus, as shown in Figures 1A and 1B. Immunoblotting indicated that the expression of
this short spleen-associated isoform of dystrophin is not affected in dystrophinopathy (Figures 1C and 1D),
but the full-length Dp427-M isoform of dystrophin was clearly shown to be absent from mdx-4cv gastroc-
nemius muscle, as illustrated in Figures 2C–2E. The histological staining of mdx-4cv muscle depicts the
typical hallmarks of X-linked muscular dystrophy, including variations in fiber diameter, a high degree of
central nucleation, fibrosis, and inflammation (Figures 2A and 2B).Mass Spectrometric Profiling of the Mouse Spleen Proteome
Prior to carrying out a comprehensive proteome-wide comparison between wild-type andmdx-4cv spleen,
it was essential to first establish how well the chosen proteomic approach covered the accessible splenic
protein constituents using total tissue extracts. The biochemical cataloging of 12-month-old mouse spleen
with the help of an Orbitrap Fusion Tribrid mass spectrometer resulted in the identification of 5,688 splenic
protein species. This table was deposited as a supplementary multi-consensus file to the Open Science
Framework repository under the following link: https://osf.io/f85ve/. In addition, individual files include
data from the analysis of 14 separate mass spectrometric sample runs (representing 7 biological repeats
of wild-type spleen preparations and 7 biological repeats of mdx-4cv spleen preparations, which were
also deposited to the OSF entry ‘‘f85ve’’) and consists of high-confidence peptides that were filtered based
on Xcorr values. Importantly, a wide range of spleen-associated proteins were confirmed to be present in
the examined tissue extracts.
Figure 3 shows a pie chart that summarizes the results from the bioinformatic PANTHER analysis of protein
families that weremass spectrometrically identified in mouse spleen preparations. Protein classes included
a variety of enzyme families, such as hydrolases, oxidoreductases, and transferases, as well as enzymemod-
ulators, nucleic acid-binding proteins, transcription factors, transporters, and cytoskeletal components.
The identification of proteins by the highest percent of sequence coverage agreed with the involvement
of the spleen with the removal of abnormal erythrocytes and the immune system. Spleen-associated pro-
teins with a protein sequence coverage above 90% included hemoglobin subunit beta-1 (P02088), hemo-
globin subunit beta-2 (P02089), and the immunoglobulin Ig kappa chain (P01654). Splenic proteins that
were identified by more than 80 peptides included the crucial cytoskeletal proteins filamin, plectin,
talin, myosin-9, myosin-11, dynein heavy chain, erythrocytic alpha/beta spectrin, and non-erythrocyticiScience 23, 101500, September 25, 2020 3
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Figure 1. Mass Spectrometric Identification of a Short Isoform of Dystrophin in Mouse Spleen
(A) Diagrammatic presentation of the DMD gene and its 7 promoters.
(B) Overview of unique peptides determined by the mass spectrometric analysis of 12-month-old mouse spleen and their
position within the carboxy terminal region of the dystrophin protein sequence
(C and D) Comparative immunoblot analysis of the apparent spleen isoform Dp71 of dystrophin in wild-type versus mdx-
4cv preparations. Lanes 1 and 2 contain wild-type and mdx-4cv specimens, respectively (C). In (D) the box plots of the
immunoblot analysis are shown (Mann-Whitney U test; n = 5; none significant). The value of molecular mass standards
(x103 kDa) is marked on the left side of the gel. A representative protein gel of spleen extracts used to produce




Articlealpha/beta spectrin, as well as prolow-density lipoprotein receptor-related protein 1 and basement mem-
brane-specific heparan sulfate proteoglycan core protein.
Of note, the proteomic survey of mouse spleen included the identification of major types of splenic recep-
tors, enzymes, and lymphoid proteins, such as cell surface antigens. The spleen marker named CD5
antigen-like protein, which was previously shown to be one of the most highly expressed splenic proteins
(Uhlén et al., 2015), was clearly identified as CD5L protein of 38.8 kDa (Q9QWK4; 47% coverage; 14 unique
peptides). Other major spleen components that were covered by the mass spectrometric survey included
the spleen-associated tyrosine kinase SYK of 71.3 kDa (P48025; 56% coverage; 25 unique peptides), the
tyrosine-protein phosphatase non-receptor type substrate 1 SIRPA of 56.4 kDa (P97797; 20% coverage; 7
unique peptides), the abundant spleen marker protein FH1/FH2 domain-containing protein FHOD1 of
129.5 kDa (Q6P9Q4; 19% coverage; 17 unique peptides), the scavenger receptor stabilin STAB2 of
277.3 kDa (Q8R4U0; 20% coverage; 32 unique peptides), CD81 antigen of 25.8 kDa (P35762; 31% coverage;
4 unique peptides), CD82 antigen of 29.6 kDa (P40237; 20% coverage; 5 unique peptides), B-cell receptor
CD22 of 96.5 kDa (P35329; 31% coverage; 17 unique peptides), B-lymphocyte antigen CD20 of 31.9 kDa
(P19437; 29% coverage; 8 unique peptides), CD209 antigen-like protein B of 37.1 kDa (Q8CJ91; 38%
coverage; 10 unique peptides), and CD2-associated protein of 70.4 kDa (Q9JLQ0; 22% coverage; 11 unique
peptides).
The screening of the experimentally accessible mouse spleen proteome revealed the coverage of major
protein constituents belonging to the family of ‘‘classical plasma proteins’’ (Anderson and Anderson,
2002), as listed in Table 2, including serum albumin; complement factors H, C3, C4-B, C5, C8, and C9; inter
alpha-trypsin inhibitor heavy chains 4, H1, H2, and H3; murinoglobulin; haptoglobin; serotransferrin; ferritin
light and heavy chains; ceruloplasmin; plasminogen; the alpha, beta, and gamma chains of fibrinogen;4 iScience 23, 101500, September 25, 2020
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Figure 2. Histological and Immunofluorescence Microscopical Characterization of Skeletal Muscle from themdx-
4cv Mouse Model of Duchenne Muscular Dystrophy
(A–D) Shown are transverse cryosections of wild-type (wt) (A and C) andmdx-4cv (B and D) gastrocnemiusmuscle stained
with hematoxylin and eosin (H&E) (A and B) and labeled with antibodies to the full-length Dp427 isoform of dystrophin (C
and D). In (E) the analysis of immunofluorescence intensities is shown (unpaired Student’s t test; mean values G SEM; n =
4; **p < 0.01). Dystrophic muscle fibers show abnormal fiber diameters, central nucleation, cellular degeneration, and




Articleplasma kallikrein and von Willebrand factor, as well as the alpha-2-HS, alpha-1B, and beta-2 glycoproteins
(Geyer et al., 2017; Moulder et al., 2018; Schwenk et al., 2017). A large number of the crucial class of serum
lipid-binding proteins was also covered by the proteomic analysis of the spleen. This included the apolipo-
proteins of classes A to M, such as apolipoproteins A-I, A-II, A-IV, A-V, B-100, C-I, C-III, C-IV, D, E, F, and M
(Table 3). Serum proteins with relevance to muscle diagnostics that are generally defined as ‘‘tissue leak
markers’’ (Anderson and Anderson, 2002) were also identified, including myoglobin of 17.1 kDa (P04247;
60% coverage; 10 unique peptides), the muscle-specific Tnnc2 isoform of troponin TnC of 18.1 kDa
(P20801; 15% coverage; 1 unique peptide), and M-type creatine kinase of 43 kDa (P07310; 49% coverage;
15 unique peptides).
Proteomic Profiling of the mdx-4cv Spleen
The comparative mass spectrometric survey of wild-type versusmdx-4cv spleen extracts identified 10.93%
change in protein constituents. Of these components, 93 protein species were identified by a coverage of
their amino acid sequence by at least 2 peptides and a minimum fold change of 1.5. A reduced expression
was found to occur in 55 proteins, and 38 proteins were shown to be increased in their abundance, as listed
in Table 4 and Table 5, respectively. The tables with the findings from the comparative proteomic analysis
provide information on accession number, protein name, gene symbol, number of unique peptides, con-
fidence score, adjusted p value, and fold change. In addition to changed proteins that were identified by at
least 2 unique peptides, another 159 decreased proteins and 145 increased proteins were identified by only
1 unique peptide (not shown). Owing to their low sequence coverage, these proteomic hits were not
included in the subsequent bioinformatic analysis of the mdx-4cv spleen. The most decreased and the
most increased spleen-associated proteins were identified as apolipoprotein B-100 (E9Q414) and pro-
tein-glutamine gamma-glutamyl-transferase TGM2 (P21981), respectively, in mdx-4cv preparations. The
heatmap of the comparative mass spectrometric survey is provided in Figure 4 and summarizes the differ-
ential expression pattern of changed proteins in wild-type versus the mdx-4cv spleen.
The bioinformatic PANTHER and STRING analyses depicted in Figure 5 summarize the proteome-wide
changes in the mdx-4cv spleen, as well as potentially altered protein-protein interaction patterns of
changed spleen-associated proteins. Both considerable decreases and increases were observed foriScience 23, 101500, September 25, 2020 5
Figure 3. Proteomic Profiling of the Mouse Spleen
Shown is the result of the bioinformatic PANTHER analysis of the distribution of protein classes within the accessible




Articlemetabolic interconversion enzymes, such as hydrolases, ligases, lyases, oxidoreductases, and transferases.
Striking increases included proteinmodifiers such as proteases, protein modulators such as protease inhib-
itors, and transfer carriers. In relation to altered protein interactions, especially striking is the apolipopro-
tein hub with ApoE and ApoB of reduced protein species. Immunofluorescence microscopy clearly
confirmed the drastic reduction of ApoE in the mdx-4cv spleen (Figures 6E, 6F, and 6J) and indicated
that the expression of the short spleen-associated isoform of dystrophin is not affected in dystrophinop-
athy (Figures 6C, 6D, and 6I). No major histological changes (Figures 6A and 6B) and comparable expres-
sion levels of the molecular chaperone HspB2 (Figures 6G, 6H, and 6K) were observed in the mdx-4cv
spleen.
Potentially excreted forms of proteins were identified as transglutaminase 2 (protein-glutamine gamma-
glutamyl-transferase TGM2) and matrix metalloproteinase MMP9. The protein band pattern of gel electro-
phoretically separated spleen samples did not show major differences between wild-type and mdx-4cv
preparations (Figure 7A). However, the increased abundance of TGM2 and MMP9 in the mdx-4cv spleen
was confirmed by immunoblotting (Figures 7B, 7C, 7E, and 7F). In contrast, the spleen-associated alpha-
subunit of the Na+/K+-ATPase showed nomajor changes in its density in the dystrophic phenotype (Figures
7D and 7G).DISCUSSION
The mdx-4cv Mouse Model of Dystrophinopathy
Spontaneous or bioengineered mdx-type mouse models of dystrophinopathy have been widely used in
muscular dystrophy research (Partridge, 2013;Wilson et al., 2017), and there are ongoing efforts to improve spe-
cific aspects of dystrophicmice to bettermirror the humanpathology (Yucel et al., 2018). Themdx-4cvmodel has
been successfully employed for the evaluation of experimental therapeutic approaches for the restoration of
dystrophin (Mitrpant et al., 2009; Kimura et al., 2010; Bengtsson et al., 2017) and the systematic identification
of novel biomarker candidates to improve differential diagnosis, prognosis, and therapy monitoring (Hathout
et al., 2014;Dowling et al., 2019). The cell biological characterization of themdx-4cvmouse,whichwas generated
by chemical mutagenesis (Chapman et al., 1989) and is characterized by a 10-fold lower rate of Dp427-positive
revertant muscle fibers as compared with the naturally occurringmdx-23mouse (Danko et al., 1992), has estab-
lished distinct pathological alterations throughout the lifetime of this animal model (Latroche et al., 2015). This
includes varying degrees of fiber degeneration, reactive myofibrosis, sterile inflammation, andmetabolic distur-
bances in limbmuscles (Murphy et al., 2019a), the diaphragm (Murphy et al., 2019b), and the heart (Murphy et al.,
2016), as well as proteome-wide alterations in the brain (Murphy et al., 2015), the liver (Murphy et al., 2018a), and6 iScience 23, 101500, September 25, 2020
Accession Protein Gene Coverage (%) Unique Peptides Molecular Mass (kDa)
P07724 Serum albumin Alb 73 47 68.6
P06909 Complement factor H Cfh 56 46 139
P01027 Complement C3 C3 50 67 186.4
P01029 Complement C4-B C4b 22 28 192.8
P06684 Complement C5 C5 22 27 188.8
Q8K182 Complement C8 alpha C8a 39 16 66j
P06683 Complement C9 C9 37 19 62
A6X935 Inter alpha-trypsin inhibitor, heavy chain 4 Itih4 34 23 104.6
Q61702 Inter-alpha-trypsin inhibitor, heavy chain H1 Itih1 26 16 101
Q61703 Inter-alpha-trypsin inhibitor, heavy chain H2 Itih2 24 16 105.9
Q61704 Inter-alpha-trypsin inhibitor, heavy chain H3 Itih3 13 8 99.3
P28665 Murinoglobulin-1 Mug1 38 43 165.2
Q61646 Haptoglobin Hp 35 11 38.7
Q921I1 Serotransferrin Tf 61 48 76.7
P09528 Ferritin heavy chain Fth1 70 14 21.1
P29391 Ferritin light chain 1 Ftl1 66 12 20.8
Q61147 Ceruloplasmin Cp 34 28 121.1
P20918 Plasminogen Plg 62 33 90.7
E9PV24 Fibrinogen alpha chain Fga 39 19 87.4
Q8K0E8 Fibrinogen beta chain Fgb 69 33 54.7
Q8VCM7 Fibrinogen gamma chain Fgg 64 23 49.4
P26262 Plasma kallikrein Klkb1 12 6 71.3
Q8CIZ8 von Willebrand factor Vwf 27 51 309.1
P29699 Alpha-2-HS-glycoprotein Ahsg 46 10 37.3
Q19LI2 Alpha-1B-glycoprotein A1bg 27 11 56.5
Q01339 Beta-2-glycoprotein 1 Apoh 46 16 38.6




Articlethe kidney (Dowling et al., 2020b). The concentration of distinct protein biomarkers is also markedly affected in
mdx-4cv serum (Murphy et al., 2017), saliva (Murphy et al., 2018b), and urine (Gargan et al., 2020). These complex
and body-wide changesmake themdx-4cvmouse a suitablemodel system to study themolecular pathogenesis
of dystrophinopathy.
The Spleen Proteome and Muscular Dystrophy
The comparative mass spectrometric analysis presented in this report is based on an excellent coverage of
the experimentally accessible spleen proteome in wild-type versus mdx-4cv extracts. Previous large-scale
surveys using both systematic mass spectrometric and antibody-based methodology have established a
wide range of spleen-associated proteins (Andersson et al., 2014; Dudekula and Le Bihan, 2016; Goltsev
et al., 2018; Thul and Lindskog, 2018; Uhlén et al., 2015; Wilhelm et al., 2014). Many of these key marker
proteins of the spleen were identified by a high degree of sequence coverage by unique peptides in
this study. In agreement with established splenic changes in dystrophic animal models of DuchenneiScience 23, 101500, September 25, 2020 7
Accession Protein Gene Coverage (%) Unique Peptides Molecular Mass (kDa)
Q00623 Apolipoprotein A-I Apoa1 53 19 30.6
P09813 Apolipoprotein A-II Apoa2 49 6 11.3
P06728 Apolipoprotein A-IV Apoa4 68 22 45
Q8C7G5 Apolipoprotein A-V Apoa5 27 8 41.2
E9Q414 Apolipoprotein B-100 Apob 19 69 509.1
P34928 Apolipoprotein C-I Apoc1 20 2 9.7
P33622 Apolipoprotein C-III Apoc3 27 2 11
Q61268 Apolipoprotein C-IV Apoc4 9 1 14.3
P51910 Apolipoprotein D Apod 6 1 21.5
P08226 Apolipoprotein E Apoe 63 20 35.8
Q91V80 Apolipoprotein F Apof 6 1 34.3
Q9Z1R3 Apolipoprotein M Apom 12 2 21.3




Articlemuscular dystrophy, such as morphological adaptations in the white pulp domain of the spleen (Santos
et al., 2013) and altered levels of immune cells in the spleen and enhanced migration of inflammatory cells
from the splenic reservoir to dystrophic muscle tissues (Farini et al., 2016; Giordano et al., 2015; Mojumdar
et al., 2014, 2016; Ouisse et al., 2019), this investigation has established considerable effects on the spleen
proteome owing to deficiency in the full-length dystrophin isoform Dp427-M. Since the spleen acts as a
dominant reservoir for inflammatory cells (Ingersoll et al., 2011) and splenic monocytes were recently shown
to play an important role during chronic inflammation of dystrophic fibers (Rizzo et al., 2020), the novel pro-
teomic findings are in agreement with the pathophysiological idea of a connection between the lymphoid
system and dystrophic muscles with an inflammatory phenotype (Villalta et al., 2015; Tidball et al., 2018).Preserved Expression of a Short Isoform of Dystrophin in the mdx-4cv Spleen
X-linkedmuscular dystrophy is a complex neuromuscular disorder that is characterized by necrosis, myofibrosis,
and inflammation in the skeletal musculature, as well as late-onset cardiomyopathy, respiratory impairments,
neurological deficiencies, scoliosis, and metabolic disturbances (Mercuri et al., 2019; Thompson et al., 2020).
The neuromuscular symptoms are due to primary abnormalities in the extremely large DMD gene, which en-
codes several isoforms of the protein dystrophin (Muntoni et al., 2003). The proteomic survey of the spleen pre-
sented here has identified unique peptides that belong to the dystrophin protein sequence. This not-well-char-
acterized spleen-associated proteoform of the dystrophin protein is most likely a short version of theDMD gene
product, such as the ubiquitously expressed Dp71-G isoform (Tokarz et al., 1998). The proteomic analysis found
the presence of this dystrophin isoform in all analyzed spleen samples with high confidence; thus, the nonsense
mutation in exon 53 of theDMDgenedoes not appear to affect theproduction of this short dystrophin isoform in
the mdx-4cv mouse (Im et al., 1996). However, immunofluorescence microscopy clearly showed that the full-
length Dp427-M isoform of dystrophin is absent from dystrophicmdx-4cv gastrocnemiusmuscle fibers (Murphy
et al., 2019a), confirming the dystrophic phenotype.Proteomic Identification of Dystrophin-Associated Proteins in the Spleen
The full-length isoform of dystrophin, Dp427-M, functions in contractile fibers as a membrane cytoskeletal
component and forms a supramolecular assembly with a variety of sarcolemma-associated proteins. The
dystrophin core complex, consisting of Dp427-M, dystroglycans, sarcoglycans, dystrobrevins, syntrophins,
and sarcospan, links the extracellular matrix component laminin to the intracellular actin cytoskeleton (Oh-
lendieck, 1996). This trans-plasmalemmal structure plays a key role in lateral force transmission and the sta-
bilization of the fiber surface during excitation-contraction-relaxation cycles (Murphy and Ohlendieck,
2015). In dystrophinopathy, the almost complete loss of Dp427-M causes a drastic reduction in the mem-
bers of the dystrophin-associated glycoprotein complex, which in turn triggers sarcolemmal micro-8 iScience 23, 101500, September 25, 2020








E9Q414 Apolipoprotein B-100 Apob 2 5.4283 0.0176 296.2
A6X935 Inter alpha-trypsin inhibitor, heavy chain
4
Itih4 2 4.6726 0.0172 163.3
Q91ZX7 Prolow-density lipoprotein receptor-
related protein 1
Lrp1 2 4.9936 0.0453 48.3
P08226 Apolipoprotein E Apoe 2 7.0306 0.0413 41.2
Q91WT9 Cystathionine beta-synthase Cbs 4 9.0211 0.0168 21.1
P03987 Ig gamma-3 chain C region – 5 13.0469 0.0168 20.3
Q6P8U6 Pancreatic triacylglycerol lipase Pnlip 2 4.9116 0.0285 15.3
P28665 Murinoglobulin-1 Mug1 5 18.5175 0.0216 8.7
P20918 Plasminogen Plg 5 14.0486 0.0264 8.2
P01027 Complement C3 C3 2 6.9290 0.0265 5.8
Q8K0C5 Zymogen granule membrane protein 16 Zg16 2 4.7425 0.0205 5.3
Q91X79 Chymotrypsin-like elastase family
member 1
Cela1 2 6.6288 0.0255 5
Q64285 Bile salt-activated lipase Cel 2 4.0527 0.0213 4.4
P32261 Antithrombin-III Serpinc1 4 13.3814 0.0174 4.2
Q9D8U3 Endoplasmic reticulum resident protein
27
Erp27 2 3.8992 0.0173 4.2
Q504N0 Carboxypeptidase A2 Cpa2 4 11.1796 0.0181 4
Q9JK88 Serpin I2 Serpini2 6 15.7950 0.0174 3.7
P07724 Serum albumin Alb 3 9.5456 0.0140 3.7
Q5BKQ4 Inactive pancreatic lipase-related protein
1
Pnliprp1 5 12.4300 0.0237 3.6
P00688 Pancreatic alpha-amylase Amy2 5 15.8377 0.0175 3.5
A6H584 Collagen alpha-5(VI) chain Col6a5 4 12.5493 0.0174 3.3
Q61024 Asparagine synthetase (glutamine-
hydrolyzing)
Asns 5 12.0815 0.0172 3.2
Q7TPZ8 Carboxypeptidase A1 Cpa1 2 9.3357 0.0239 3
Q9CR35 Chymotrypsinogen B Ctrb1 2 4.0493 0.0361 3
D3Z6P0 Protein disulfide-isomerase A2 Pdia2 11 34.7523 0.0173 2.9
P21614 Vitamin D-binding protein Gc 4 10.5449 0.0298 2.9
Q61838 Pregnancy zone protein Pzp 11 30.1861 0.0268 2.8
P15947 Kallikrein-1 Klk1 3 7.0787 0.0276 2.8
P49290 Eosinophil peroxidase Epx 5 13.9853 0.0169 2.7
P07758 Alpha-1-antitrypsin 1-1 Serpina1 4 13.4458 0.0233 2.5
Table 4. Decreased Proteins in the mdx-4cv Spleen as Determined by LC-MS/MS Analysis
(Continued on next page)
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P23953 Carboxylesterase 1C Ces1c 3 10.9205 0.0292 2.5
Q8VDJ3 Vigilin Hdlbp 2 5.4235 0.0301 2.5
P50172 Corticosteroid 11-beta-dehydrogenase
isozyme 1
Hsd11b1 2 5.8113 0.0207 2.3
Q921I1 Serotransferrin Tf 9 25.5997 0.0268 2.2
Q00897 Alpha-1-antitrypsin 1-4 Serpina1d 3 9.79536 0.0314 2
Q64511 DNA topoisomerase 2-beta Top2b 2 4.0629 0.0477 1.9
P15626 Glutathione S-transferase Mu 2 Gstm2 3 10.3769 0.0340 1.8
Q9D855 Cytochrome b-c1 complex subunit 7 Uqcrb 3 8.1900 0.0126 1.8
Q8R2E9 ERO1-like protein beta Ero1b 2 4.7424 0.0168 1.8
Q62087 Serum paraoxonase/lactonase 3 Pon3 4 13.6453 0.0167 1.7
Q99K85 Phosphoserine aminotransferase Psat1 4 11.5566 0.0174 1.7
Q9DBF1 Alpha-aminoadipic semialdehyde
dehydrogenase
Aldh7a1 4 10.4946 0.0308 1.7
O08807 Peroxiredoxin-4 Prdx4 3 8.6493 0.0172 1.7
P61620 Protein transport protein Sec61 subunit
alpha isoform 1
Sec61a1 3 11.7206 0.0167 1.7
Q06138 Calcium-binding protein 39 Cab39 2 5.5638 0.0338 1.7
P10852 4F2 cell-surface antigen heavy chain Slc3a2 4 12.8087 0.0122 1.6
P09103 Protein disulfide-isomerase P4hb 4 10.0713 0.0189 1.6
P58252 Elongation factor 2 Eef2 3 9.4214 0.0256 1.6
Q6ZWQ7 Signal peptidase complex subunit 3 Spcs3 2 4.2641 0.0210 1.6
P35564 Calnexin Canx 2 5.9499 0.0312 1.6
Q78PY7 Staphylococcal nuclease domain-
containing protein 1
Snd1 5 13.1260 0.0295 1.5
O35855 Branched-chain-amino-acid
aminotransferase, mitochondrial
Bcat2 2 6.0829 0.0174 1.5
Q64674 Spermidine synthase Srm 2 5.6741 0.0172 1.5
Q922Q8 Leucine-rich repeat-containing protein
59
Lrrc59 2 4.9835 0.0170 1.5





Articlerupturing and calcium-induced proteolytic degradation (Guiraud et al., 2015). Here, we have extended the
characterization of dystrophin-associated glycoproteins to the spleen and have identified by mass spec-
trometry the presence of dystroglycan, sarcoglycans, dystrobrevin, and syntrophins in this crucial second-
ary lymphoid organ.Drastic Reduction of Apolipoproteins and Related Serum Proteins in the mdx-4cv Spleen
A variety of complex changes in the immunobiology of dystrophic skeletal muscles have been established
that might be reflected by variations in the lymphoid system (Villalta et al., 2015; Lozanoska-Ochser et al.,10 iScience 23, 101500, September 25, 2020










Tgm2 2 4.74003 0.0124 3.8
P01878 Ig alpha chain C region – 2 5.5789 0.0332 2.9
Q8CJ91 CD209 antigen-like protein B Cd209b 2 5.1658 0.0152 2.5
P41245 Matrix metalloproteinase-9 Mmp9 2 5.9333 0.0175 2.3
P08071 Lactotransferrin Ltf 15 49.8443 0.0136 2.1
P54869 Hydroxymethylglutaryl-CoA synthase,
mitochondrial
Hmgcs2 3 7.7425 0.0130 2
P21300 Aldo-keto reductase family 1 member B7 Akr1b7 2 5.8779 0.0183 2
P50608 Fibromodulin Fmod 2 4.9599 0.0190 1.9
Q3UMY5 Echinoderm microtubule-associated
protein-like 4
Eml4 2 6.1649 0.0120 1.9
P82343 N-acylglucosamine 2-epimerase Renbp 2 6.3056 0.0170 1.9
O08692 Neutrophilic granule protein Ngp 2 5.4646 0.0185 1.9
P26039 Talin-1 Tln1 2 5.7934 0.0181 1.8
Q9CWK8 Sorting nexin-2 Snx2 2 6.9348 0.0183 1.8
Q8VEE1 LIM and cysteine-rich domains protein 1 Lmcd1 2 6.8011 0.0085 1.8
P19070 Complement receptor type 2 Cr2 2 5.0366 0.0295 1.8
P27870 Proto-oncogene vav Vav1 3 7.4085 0.0192 1.7
Q9ES52 Phosphatidylinositol 3,4,5-trisphosphate
5-phosphatase 1
Inpp5d 3 8.2105 0.0152 1.7
Q8R1G6 PDZ and LIM domain protein 2 Pdlim2 2 6.4459 0.0286 1.7
Q6P8X1 Sorting nexin-6 Snx6 2 6.9493 0.0176 1.7
P49710 Hematopoietic lineage cell-specific
protein
Hcls1 2 6.3795 0.0295 1.7
P63038 60 kDa heat shock protein, mitochondrial Hspd1 2 4.9004 0.0312 1.7
Q61823 Programmed cell death protein 4 Pdcd4 2 5.2918 0.0147 1.7
Q6P4T2 U5 small nuclear ribonucleoprotein
200 kDa helicase
Snrnp200 2 6.1287 0.0154 1.7
Q62230 Sialoadhesin Siglec1 6 19.4232 0.0124 1.6
Q8VCW8 Medium-chain acyl-CoA ligase ACSF2,
mitochondrial
Acsf2 5 16.0841 0.0118 1.6
Q9QVP9 Protein-tyrosine kinase 2-beta Ptk2b 3 11.6718 0.0265 1.6
Q8K2T1 NmrA-like family domain-containing
protein 1
Nmral1 3 9.4830 0.0122 1.6
Q921T2 Torsin-1A-interacting protein 1 Tor1aip1 2 4.2835 0.0135 1.6
Q3UP87 Neutrophil elastase Elane 2 4.6109 0.0260 1.6
Table 5. Increased Proteins in the mdx-4cv Spleen as Determined by LC-MS/MS Analysis
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Q99KQ4 Nicotinamide phosphoribosyltransferase Nampt 2 6.6515 0.0164 1.6
Q9QXS1 Plectin Plec 11 34.4355 0.0152 1.5
Q80SU7 Gvin1 Gvin1 4 12.9185 0.0293 1.5
P05555 Integrin alpha-M Itgam 4 11.3340 0.0157 1.5
Q62261 Spectrin beta chain, non-erythrocytic 1 Sptbn1 3 10.1324 0.0265 1.5
O70318 Band 4.1-like protein 2 Epb41l2 2 4.2166 0.0138 1.5
P23475 X-ray repair cross-complementing
protein 6
Xrcc6 2 6.1252 0.0180 1.5
Q9CQE5 Regulator of G-protein signaling 10 Rgs10 2 5.1948 0.0124 1.5





Article2018; Tidball et al., 2018). The most striking finding of this investigation is the drastic reduction in a variety
of serum proteins in the mdx-4cv spleen. This includes proteins that are involved in lipid transport and
metabolism (apolipoproteins ApoB-100 and ApoE, lipoprotein receptor Lrp1, and various lipases), the
complement system (complement C3), metabolite transportation (albumin), digestion (amylase), and fac-
tors involved in the acute response and inflammation (kallikrein, inter alpha-trypsin inhibitor). Spleen-asso-
ciated proteins with a drastic reduction in the mdx-4cv mouse model were previously shown to be also
reduced inmdx-4cv serum (Murphy et al., 2017). This included themost significantly decreased protein spe-
cies in themdx-4cv spleen, apolipoprotein B-100, as well as antithrombin-III, complement C3, alpha-1-anti-
trypsin, murinoglobulin-1, plasminogen, inter-alpha-trypsin inhibitor heavy chain, chymotrypsin-like elas-
tase, vitamin D-binding protein, and serotransferrin.
Apolipoproteins are crucial plasma proteins involved in the regulation of lipid homeostasis, and their con-
centration is a good indicator of the metabolic status of the organism (Geyer et al., 2017). Surprisingly, in
the ApoE-null mdx mouse reduced atherosclerotic plaque formation was found, as well as decreased
numbers of CD3+ cells in the spleen (Shami et al., 2015). In the case of the mdx-4cv model of dystrophin-
opathy, the reduced abundance of these plasma proteins in the spleen could reflect their lower concentra-
tion in the circulatory system. Impaired blood flow due to weakened cardiac output of the dystrophin-defi-
cient heart might also be a crucial factor that causes a decrease in plasma components in the mdx-4cv
spleen. In dystrophinopathy, late-onset cardiomyopathy causes cardiac weakness (Finsterer and Cripe,
2014) and this is reflected by drastic proteome-wide changes especially at the level of metabolic enzymes
(Murphy et al., 2016). This cardiac impairment could cause a decreased rate of circulation of blood and
concomitant chronic lack of proper supply of oxygen and nutrients to peripheral organs. The proteomic
findings on the mdx-4cv spleen presented here agrees with this pathophysiological concept.Increased Transglutaminase TGM2 and Matrix Metalloproteinase MMP9 in the mdx-4cv
Spleen
The most increased protein in the mdx-4cv spleen was identified as protein-glutamine gamma-glutamyl-
transferase TGM2, also more commonly referred to as transglutaminase 2, which is a multi-functional
enzyme that mediates the cross-linking of proteins and catalyzes the conjugation of polyamines to proteins
(Beninati et al., 2017). In addition, more recently transglutaminase 2 was shown to be intrinsically involved in
the maintenance of proteostasis (D’Eletto et al., 2019). Since chronic cellular stress results in the increased
occurrence of abnormal protein folding or detrimental protein aggregation, the regulation of chaperone
function is upregulated under dystrophic conditions (Doran et al., 2006; Brinkmeier and Ohlendieck, 2014).
Thus, the elevated levels of transglutaminase TGM2 might be involved in a key aspect of the regulation of
protein homeostasis in the stressed mdx-4cv spleen. The increased abundance of the matrix metallopro-
teinase MMP9 agrees with the findings from the previous screening of serum from themdxmouse and pa-
tients with Duchenne muscular dystrophy for minimally invasive biomarker candidates (Nadarajah et al.,12 iScience 23, 101500, September 25, 2020
Figure 4. Heatmap of the Comparative Proteomic Analysis of Wild-Type versus mdx-4cv Spleen
Shown are the findings from hierarchical clustering of the mean protein expression values of statistically significant




Article2011; Hathout et al., 2014; Anaya-Segura et al., 2015). The serum-associated proteoform of this member of
the large family of matrix metalloproteinases was shown to be increased significantly in muscular dystro-
phy, which might explain its elevated levels in the mdx-4cv spleen. Although MMP9 probably plays a dif-
ferential role during the progression of muscle degeneration (Shiba et al., 2015), its primary effect in
muscular dystrophy appears to be the promotion of inflammation, tissue remodeling, and reactive myofib-
rosis (Kherif et al., 1999; Hindi et al., 2013; Shin et al., 2013). This confirmsMMP9 as a good biomarker candi-
date for secondary changes in muscular dystrophy due to sterile inflammation and fibrotic changes.iScience 23, 101500, September 25, 2020 13
Figure 5. Bioinformatic Analysis of Proteomic Changes in the mdx-4cv Spleen
Overview of the distribution of changed protein classes and potential protein-protein interaction patterns of decreased
versus increased proteoforms in the spleen from the mdx-4cv mouse model of Duchenne muscular dystrophy, as




ArticleNovel Biomarker Candidates of Muscular Dystrophy-Associated Changes in the Spleen
In conclusion, although the expression levels of a short spleen-associated dystrophin isoform and its associated
proteins do not appear to be majorly affected in muscular dystrophy, the absence of the full-length dystrophin
isoform in contractile tissues seems to trigger secondary effects in the lymphoid system. This includes a drastic
reduction in the apolipoproteins ApoB-100 and ApoE and a concomitant increase in the enzyme protein-gluta-
mine gamma-glutamyl-transferase TGM2 and the matrix metalloproteinase MMP9, which might be useful can-
didates as novel biomarkers of dystrophinopathy-related changes in the spleen (Dowling et al., 2019; Al-Khalili
Szigyarto, 2020). The proteomic findings suggest that pathophysiological cross talk and/or anatomical intercon-
nectivity affects the spleen in muscular dystrophy, which substantiates the appropriateness of the mdx-4cv
mouse model for studying secondary changes in non-muscle tissues in dystrophinopathy.
Limitations of the Study
In this report, we have characterized for the first time the secondary impact of dystrophin deficiency on the
spleen and established considerable proteome-wide changes in this lymphoid organ. However, the study






Figure 6. Histological and Immunofluorescence Microscopical Characterization of the Spleen from the mdx-4cv
Mouse Model of Duchenne Muscular Dystrophy
(A–H) Shown are transverse cryosections of wild-type (wt) (A, C, E, and G) andmdx-4cv (B, D, F, and H) spleen stained with
hematoxylin and eosin (H&E) (A and B) and labeled with antibodies to dystrophin (Dys) (C and D), apolipoprotein ApoE (E
and F), and the molecular chaperone HspB2 (G and H).





Articlemilder pattern of neuromuscular degeneration in most skeletal muscles as compared with patients with
Duchenne muscular dystrophy. It will therefore be crucial to extend these studies in the future to the eval-
uation of secondary abnormalities in X-linked muscular dystrophy to patient specimens. Although compar-
ative proteomics is an excellent bioanalytical approach to determine systematic changes in the dystrophic
phenotype, mass spectrometric lists of altered protein expression levels do neither give detailed informa-
tion on the pathobiochemical time course of cellular alterations nor provide a deep mechanistic under-
standing of disease progression. Thus, based on the comparative proteomic data supplied in this report,
it will be crucial to further study the underlying disturbances that cause proteome-wide changes in the
spleen in association with dystrophinopathy.
Resource Availability
Lead Contact
For further information, requests should be directed to the Lead Contact: Kay Ohlendieck (kay.
ohlendieck@mu.ie).iScience 23, 101500, September 25, 2020 15
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Figure 7. Immunoblot Analysis of the Spleen from the mdx-4cv Mouse Model of Duchenne Muscular Dystrophy
(A–D) Shown is a protein gel of wild-type (wt) versus mdx-4cv spleen samples (A) and identical nitrocellulose replicas
labeled with an antibody to matrix metalloproteinase MMP9 (B), transglutaminase TGM2 (C), and Na+/K+-ATPase (D).
Lanes 1 and 2 contain wild-type and mdx-4cv specimens, respectively.
(E–G) In panels (E–G) the box plots of the immunoblot analysis are shown (Mann-Whitney U test; n = 7; *p < 0.05; **p <





This study did not generate new unique reagents.
Data and Code Availability
The proteomic datasets from the mass spectrometric analysis of 14 separate spleen sample runs have been
deposited to the Open Science Framework repository as OSF entry ‘‘f85ve’’ under the following link:
https://osf.io/f85ve/. This link also features a multi-consensus file of the proteomic cataloging of mouse
spleen with the help of an Orbitrap Fusion Tribrid mass spectrometer.METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2020.101500.ACKNOWLEDGMENTS
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MATERIALS AND METHODS 
 
Materials 
For the mass spectrometry-based proteomic analysis of spleen preparations, general materials 
and analytical grade reagents were obtained from Bio-Rad Laboratories (Hemel-Hempstead, 
Hertfordshire, UK), GE Healthcare (Little Chalfont, Buckinghamshire, UK) and Sigma 
Chemical Company (Dorset, UK). Protease inhibitors were purchased from Roche Diagnostics 
(Mannheim, Germany). Protein digestion was carried out with sequencing grade-modified 
trypsin, Lys-C and Protease Max Surfactant Trypsin Enhancer from Promega (Madison, WI, 
USA). The Pierce 660-nm Protein Assay reagents and Invitrogen NuPAGE Novex Bis-Tris 
gels were purchased from ThermoFisher Scientific (Dublin, Ireland). Vivacon 500 filter units 
were purchased from Sartorius (Göttingen, Germany). Expedeon InstantBlue Coomassie 
Protein Stain was from Abcam (Cambridge, MA, USA). Primary antibodies were purchased 
from Antibody Genie, Dublin, Ireland (CAB16344 against apolipoprotein ApoE), Cell 
Signaling Technology, Leiden, The Netherlands (mAb23565 against the alpha-subunit of the 
Na+/K+-ATPase), Abbexa Ltd, Cambridge, UK (abx001907 against heat shock protein HspB2; 
abx000934 against transglutaminase TGM2), Leica Biosystems, Wetzlar, Germany (NCL-
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DYS1 and NCL-DYS2 against dystrophin) and R&D Systems, Abingdon, UK (AF909 against 
matrix metalloproteinase MMP9; MAB4376 against transglutaminase TGM2). Anti-rabbit and 
anti-mouse peroxidase conjugated secondary antibodies were from Cell Signaling Technology 
(Leiden, The Netherlands). Normal goat serum, goat anti-mouse IgG RRX (Rhodamine Red-
X), anti-rabbit Alexa Fluor 488 and Alexa 647 antibodies were purchased from Molecular 
Probes, Life Technologies (Darmstadt, Germany) and Jackson ImmunoResearch (West Grove, 
PA, USA), respectively. The embedding medium Fluoromount G was from Southern Biotech 
(Birmingham, AL, USA). 
 
Preparation of mouse tissue extracts for proteomic and biochemical analysis 
Mice were obtained from the Bioresource Unit of the University of Bonn (Murphy et al., 
2019a), where they were kept under standard conditions and all procedures adhered to German 
legislation on the use of animals in experimental research (Amt für Umwelt, Verbraucherschutz 
und Lokale Agenda der Stadt Bonn, North Rhine-Westphalia, Germany). The spleen and 
gastrocnemius muscle from 12-month old male wild type C57/BL6 mice and age-matched 
dystrophic male mdx-4cv mice were freshly dissected and quick-frozen in liquid nitrogen. 
Tissue specimens were transported to Maynooth University in accordance with the Department 
of Agriculture (animal by-product register number 2016/16 to the Department of Biology, 
National University of Ireland, Maynooth) on dry ice and stored at -80oC prior to proteomic 
and biochemical analysis. For sample preparation, 25 mg of mouse tissues (wild type versus 
dystrophic phenotype) were lysed by homogenisation with 200µl of lysis solution (4% SDS, 
100mM Tris-Cl pH 7.6, 0.1M dithiothreitol) and incubated at 95°C for 3 minutes and then 
sonicated for 30 seconds. The lysate was clarified by centrifugation at 16,000xg for 5 minutes. 
Tissue aliquots were used for gel electrophoretic separation and comparative immunoblotting. 
Spleen extracts were further processed for mass spectrometry. 10µl of lysate was mixed with 
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200µl of 8M urea, 0.1M Tris pH 8.9 in filter units (Sartorius, Vivacon 500, Product number: 
VN0H22) and centrifuged at 14,000xg for 15 minutes. Samples were subsequently processed 
according to the standardized FASP protocol for filter-aided sample preparation (Wiśniewski, 
2009). 
 
Label-free liquid chromatography mass spectrometry 
For the proteomic profiling of the mdx-4cv spleen, reverse-phased capillary high-pressure 
liquid chromatography was performed with the help of the UltiMate 3000 nano system from 
Thermo Scientific coupled directly in-line with the Thermo Orbitrap Fusion Tribrid Mass 
Spectrometer (Murphy et al., 2019b). The digested protein samples (1µl ~ 800ng peptide) were 
loaded onto the trapping column (PepMap100, C18, 300 µm × 5 mm) at a flow rate of 25 µl/min 
with 2% (v/v) acetonitrile (ACN), 0.1% (v/v) trifluoroacetic acid (TFA) for 3 minutes before 
being resolved onto an analytical column (Acclaim PepMap 100, 75 µm × 50 cm, 3 µm bead 
diameter column). Peptides were eluted using the following binary gradient; solvent A (0.1% 
(v/v) formic acid in LC-MS grade water) and solvent B (80% (v/v) ACN, 0.08% (v/v) formic 
acid in LC-MS grade water) using 2-23% B for 75 minutes, 32-90% B for 5 minutes and 
holding at 90% B for 5 minutes at a flow rate of 300 nl/min. For peptide ionization, a voltage 
of 2.0 kV was applied and a capillary temperature of 320°C was used. Data-dependent 
acquisition with full scans in the 380-1500 m/z range was performed using an Orbitrap mass 
analyser with a resolution of 120,000 (at m/z 200), a targeted automatic gain control (AGC) 
value of 4E+05 and a maximum injection time of 50ms. The number of selected precursor ions 
for fragmentation was determined by the top-speed acquisition algorithm. Selected precursor 
ions were isolated in the Quadrupole with an isolation width of 1.6 Da. Peptides with a charge 
state of 2+ to 7+ were analysed and a dynamic exclusion was applied after 60s. Precursor ions 
were fragmented using higher energy collision-induced dissociation with a normalized 
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collision energy of 28%, and resulting MS/MS ions were measured in the linear ion trap. The 
typical MS/MS scan conditions were as follows: a targeted AGC value of 2E+04 and a 
maximum fill time of 35ms. 
 
Data analysis 
Qualitative data analysis, using mass spectrometric files (.raw), was performed by searching 
against the UniProtKB-SwissProt Mus musculus database with Proteome Discoverer 2.2 using 
Sequest HT (Thermo Fisher Scientific), and Percolator. The following search parameters were 
used for protein identification: (i) peptide mass tolerance set to 10 ppm, (ii) MS/MS mass 
tolerance set to 0.02 Da, (iii) an allowance of up to two missed cleavages, (iv) carbamido-
methylation set as a fixed modification and (v) methionine oxidation set as a variable 
modification. Peptides were filtered using a minimum XCorr score of 1.5 for 1, 2.0 for 2, 2.25 
for 3 and 2.5 for 4 charge states, with peptide probability set to high confidence (Qu et al, 
2017). 
Quantitative label-free data analysis was performed using Progenesis QI for Proteomics 
(version 2.0; Nonlinear Dynamics, a Waters company, Newcastle upon Tyne, UK), essentially 
as recommended by the manufacturer (www.nonlinear.com). Peptide and protein identification 
from this analysis were achieved with Proteome Discoverer 2.2 using Sequest HT (Thermo 
Fisher Scientific), and Percolator as described above and were imported into Progenesis QI 
software for further analysis.  
Protein identifications were reviewed, and only those which passed the following criteria were 
considered differentially expressed between experimental groups with high confidence and 
statistical significance: (i) an ANOVA p-value of ≤0.01 between experimental groups; (ii) 
proteins with ≥2 unique peptides contributing to the identification. To calculate the maximum 
fold change for a protein, Progenesis QI calculates the mean abundance for that protein in each 
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experimental condition. These mean values are then placed in a condition-vs-condition matrix 
to find the maximum fold change between any two condition’s mean protein abundances.  
The freely available software packages PANTHER (Mi et al., 2017; http://pantherdb.org/) and 
STRING (Szklarczyk et al., 2019; https://string-db.org/) were used to identify protein classes 
and characterise potential protein interactions, respectively. 
 
Gel electrophoresis and immunoblotting 
Protein fractions (12.5µg protein per lane for Coomassie Blue staining; and 25µg protein per 
lane for immunoblot analysis) were run on NuPAGE Novex Bis-Tris Gels under standard 
conditions (Murphy et al., 2019a). Protein concentration was determined using the Pierce 660-
nm protein assay system (Antharavally et al., 2009). For comparative analyses, Coomassie 
staining of protein gels was carried out with InstantBlue Coomassie Protein Stain. 
Immunoblotting was then employed as an orthogonal method for the independent verification 
of changes in newly identified proteins in the mdx-4cv spleen. Proteins were transferred to 
nitrocellulose membranes, blocked and incubated with primary antibody overnight, followed 
by detection with peroxidase-conjugated secondary antibodies using the enhanced 
chemiluminescence method (Murphy et al., 2019a). Densitometric scanning and statistical 
analysis of immunoblots was performed using a HP PSC-2355 scanner and ImageJ software 
(NIH, Bethesda, MD, USA) along with Microsoft Excel in which statistical significance was 
based on a p-value ≤ 0.05. 
 
Histological analysis and immunofluorescence microscopy 
Tissue cryo-sections from skeletal muscle and spleen were used for standardized histological 
and immunofluorescence microscopical analysis (Dowling et al., 2020). The mutant status of 
the mdx-4cv mouse was established by demonstrating the loss of the dystrophin isoform 
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Dp427-M in gastrocnemius muscle and correlated to potential changes in the spleen. 
Histological features of the analysed tissues were visualized by haematoxylin and eosin 
staining. For immunofluorescence microscopy, freshly dissected spleen and skeletal muscle 
specimens from 12-month old wild type and mdx-4cv mice were quick-frozen in liquid 
nitrogen-cooled isopentane and 10µm sections cut in a cryostat. For dystrophin immuno-
staining, unfixed cryosections were boiled in phosphate-buffered saline for 5 minutes as 
previously described in detail (Murphy et al., 2019b). For immuno-staining, sections were fixed 
in a 1:1 (v/v) mixture of methanol and acetone for 10 minutes at room temperature and then 
blocked with 1:20 diluted normal goat serum for 30 minutes at room temperature. Primary 
antibodies were diluted appropriately in phosphate-buffered saline for overnight incubation at 
4oC. Tissue specimens were carefully washed and then incubated with fluorescently labelled 
secondary antibodies, using either 1:200 diluted anti-rabbit Alexa Fluor 488 or 647 antibodies 
or 1:200 diluted anti-mouse RRX antibody for 45 minutes at room temperature. Nuclei were 
counter-stained with 1μg/ml bis-benzimide Hoechst 33342. Antibody-labelled spleen and 
skeletal muscle sections were embedded in Fluoromount G medium and viewed under a Zeiss 
Axioskop 2 epifluorescence microscope equipped with a digital Zeiss AxioCam HRc camera 
(Carl Zeiss Jena GmbH, Jena, Germany). Immunofluorescence intensity was analysed using 
ImageJ software (NIH, Bethesda, MD, USA) along with Microsoft Excel in which statistical 
significance was based on a p-value ≤ 0.05. 
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